Join the Ibalizumab group to help and get support from people like you.
Ibalizumab News
Theratechnologies Announces FDA Approval of Trogarzo 90-Second Intravenous (IV) Push Loading Dose
Updated label means new Trogarzo® patients no longer require initiation of treatment by 30-minute infusion Complete IV push method enables easier and more convenient administration of Trogarzo® for h...
Theratechnologies’ Trogarzo Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
MONTREAL, Oct. 03, 2022 (GLOBE NEWSWIRE) – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerc...
FDA Approves Trogarzo (ibalizumab-uiyk) for Treatment-Experienced Patients with Multidrug Resistant HIV
March 6, 2018 – Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple...